A Plea for Economically Sustainable Evidence-based Guidelines.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35999118.
- Also identified by DOI 10.1016/j.eururo.2022.08.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.
Medical subject headings
- Prostatic Neoplasms